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The bactericidal activity of gatifloxacin in plasma 
and urine 
Richard Wise and lennfer 111. Andrews 
Department of Microbiology, City Hospital NHS Trust, Dudley Road ,  Birmingham, UK 
Objective: To investigate the bactericidal activity of gatifloxacin in  serum and urine against relevant pathogens. 
Methods: Serum and urine samples obtained in  a single rising dose pharmacokinetic study were investigated for 
bactericidal activity. The doses employed were placebo, and 200, 400, 600 and 800 m g  of gatifloxacin. 
Results: The titers obtained reflected the dose and susceptibility of the pathogen. In serum a titer of r l : 8  was observed 
for Escherichia coli for >24 h after 400 mg; for Staphylococcus aureus and Acinetobacter baurnanii the titer was r l : 8  
for between 12-24 h after 600 mg; for Serratia marcescens it was ?1:8 for >12 h following 800 mg; and for Streptococcus 
pneurnoniae it was >1:8 for 8 h following 800 mg. In urine, the titers were greater, and for Escherichia coli, 
Staphylococcus saprophyticus, froteus rnirabilis and Enterococcus faecalis the titer was >1:8 for 12-24 h after 200 mg 
and for 24-36 h after a 400-mg dose. fseudornonas aeruginosa demonstrated a titer of >1:8 for 18-24 h following 
600 mg. 
Conclusions: These data suggest that gatifloxacin should be efficacious for a wide range of systemic and urinary tract 
infections. 
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Gatifloxacin (CG 5501, AM 1155) is a methyl- 
piperazinyl substituted fluoroquinolone with enhanced 
activity, compared with ciprofloxacin, against Gram- 
positive bacteria, yet retaining good activity against 
Gram-negative pathogens [1,2]. The agent is under 
clinical investigation in the therapy of urinary and 
respiratory tract infections. 
In the assessment of a new agent, the bactericidal 
activity of plasma and other body fluids is a relevant 
pharmacodynamic parameter, being an integration of 
pharmacokinetic properties with in vitro activity 131. 
In this investigation, the serum and urine samples 
obtained in a single oral rising dose pharmacokinetic 
study were examined for their bactericidal activity 
against a range of relevant bacterial pathogens. 
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MATERIALS AND METHODS 
Sample collection 
A single rising dose, double-blind, placebo-controlled 
study of the pharmacokinetics of gatifloxacin was 
performed by the Institute Aster, Hospital Cognacq-Jay 
in Paris, France. Four parallel groups of healthy male 
volunteers received 200, 400, 600 or 800 mg of 
gatifloxacin or placebo. In all but the 800-nig group, 12 
subjects received the active agent and three the placebo: 
in the 800-mg group, six subjects received the active 
agent and two a placebo. The volunteers participated 
after written informed consent had been obtained, after 
physical examination and when hematologic, bio- 
chemical, ECG and EEG tests were within normal 
limits. 
Blood samples were collected before and at 0.5, 1, 
2, 6, 8, 12, 18, 24, 30 and 36 h after dosing. Urine 
collection was undertaken before dosing and then at 
0-3, 3-4, 6-9, 9-12, 12-18, 18-24 and 24-36 h post- 
dose. Samples were also collected for pharmacokinetic 
analysis, which will be the subject of a separate report. 
All samples were stored at - 2 O O C  and transported 
to this laboratory. 
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Bacterial strains 
For both urine and plasma samples, Escherichia coli 
ATCC 25922 was studied. For urine samples, clinical 
isolates of Staphylococcus saprophyticus, Proteus mirabilis, 
Enterococcus faecalis and Pseudomonas aeruginosa were 
included. For plasma samples, Staphylococcus aureus 
ATCC 29213 and clinical isolates of Streptococcus 
pneumoniae, Acinetobacter baumanii and Serratia marcescens 
were studied. 
Bactericidal activity 
The minimum inhibitory and bactericidal concen- 
trations of gatifloxacin against these bacteria were 
determined by standard methodology [2]. 
The plasma bactericidal procedure was based on 
that described by the National Committee for Clinical 
Laboratory Standards (NCCLS) [4]. Briefly, plasma 
samples were double diluted in MueUer-Hinton (MH) 
broth from 1:2 to 1:2048 in 96-well microtiter trays. 
Organism suspensions were prepared by inoculating 
MH broth and then incubating, with shaking, at  
35-37OC for 3-4 h. Growth was then adjusted with 
MH broth to give an optical density equivalent to a 0.5 
McFarland standard (approximately 1 O8 organisms/mL). 
Cultures were further diluted in MH broth as follows: 
Enterobacteriaceae and Pseudomonas aeruginosa 1 :200 
and staphylococci 1 : l O O .  This final suspension was 
added in an equal volume to the diluted plasma (final 
inoculum lo5 CFU/mL). This final range of dilutions 
after the addition of organism was 1:2 to 1:4096. 
For pneumococci, the method was somewhat 
different. Preliminary experiments had shown that 
growth was so rapid in 5% lysed horse blood in MH 
broth that endpoints could not be determined. 
Dilutions of plasma were therefore made in plasma 
rather than MH broth as previously described. 
Organism suspensions were prepared initially in MH 
broth, followed by further dilution (1: lO)  in 10% lysed 
horse blood in MH broth. Viable counts were 
performed on these suspensions to check the final 
inoculum size (data not shown). 
After being sealed with an adhesive cover, plates 
were incubated at 35-37OC for 18-20 h. 
Bactericidal levels were determined by sub- 
culturing (in duplicate) 10 pL of sample from all wells 
with no visible growth (plates read with the aid of a 
microtiter viewer) onto Columbia agar (Oxoid, 
Basingstoke, UK) supplemented with 5% whole horse 
blood and 50 mmol/L magnesium chloride (previous 
experiments had shown that this concentration of 
magnesium chloride is necessary to neutralize the effect 
of residual quinolone-data not shown). PNPG (1,4- 
nitrophenyl glycarol) 50 mg/L was also added to plates 
used for the subculture of Proteus species. Plates were 
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incubated at 35-37OC for 48 h before examination. 
The number of colonies growing was determined 
manually and the plasma dilution which demonstrated 
99.9% killing was taken as the bactericidal dilution. 
Urine samples were handled in a similar fashion; 
however, dilutions of urine were made in pooled, 
filtered human urine adjusted to pH 6 and the dilution 
range was 1:2 to 16 320. 
In analysis of the data the reciprocals of the 
geometric mean of the titers obtained were utilized and 
a titer of <1:2 (i.e. a bactericidal effect of a diluted 
sample) or no effect was expressed as <2. 
The MICs and MBCs of the pathogens studied are 
shown in Table 1. Except in the case of Pseudomonas 
aeruginosa and Acinetobacter baumanii, there was only a 
2-4-fold difference between the MIC and MBC. In 
Tables 2 and 3 the reciprocals of the geometric means 
of the bactericidal titers are shown. The placebo data 
are not shown, all titers being < 1:2. An analysis of the 
individual titers for each organism a t  any one time 
point revealed a range, which was usually three 
dilutional steps but did not exceed four; that is, the 
greatest range might, for example, be 1:8 to 1:128. 
In serum, there was an increasing titer with 
increasing dose, and higher titers were seen with the 
more susceptible pathogens. With Escherichia coli, a titer 
of > 1:8 was observed for up to 4 h after a 200-mg dose 
and for up to >24 h after 400 mg. For the strain of 
Staphylococcus aureus, a titer of > 1% was also seen for up 
to 4 h after 200 mg, and after 600 mg this titer was 
exceeded for between 12 and 24 h. With Acinetobacter 
baumanii the titer was 1:8 after 8 h following 200 mg, 
and > 1:8 for 24 h following 600 mg. Against Serratia 
marcescens, the titer was >1:8 for 8 h after 400 mg and 
> 12 h following 800 mg. Titers against Streptococcus 
pneumoniae of > 1:8 were not observed for the 200- or 
Table 1 
azainst test strains 
Activity of gatifloxacin: MICs and MBCs (mg/L) 
MIC 
ATCC 25922 
ATCC 29216 
ATCC 49619 
K583 
K666 
P60 
J424 
GI67 
T398 
Escherichia coil 
Staphylocorrus aureus 
Streptococcus pneumonia 
AcinetoDacter baurnarrii 
Serratia marcescens 
Stuphylororrus saprophyticus 
Proteus mirabilis 
Reudomonas aeruginosa 
Enrerococcur faecalis 
0.05 
0.12 
0.25 
0.06 
1 
0.05 
0.25 
0.5 
1 
MBC 
0.03 
1 
0.5 
2 
2 
0.05 
1 
16 
2 
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Table 2 
Time Dose Escherichia coli Staphylococcus aureus Streptococcus pneumoniae Aciwetobacter baumanii Serratia maresfens 
Serum bactericidal activity of gatifloxacin (as reciprocal of geometric mean titer) at differing titers post dose. 
0 
1 
2 
4 
8 
12 
24 
0 
1 
2 
4 
8 
12 
24 
0 
1 
2 
3 
8 
12 
24 
0 
1 
4 
8 
12 
24 
3 - 
200 < 2  
9.5 
14.3 
Y.5 
6.0 
4 0 
1.1 
400 <2 
60 4 
85 4 
85 4 
h!) 4 
42 7 
12 0 
600 <2 
186 8 
373 6 
397 9 
225 7 
106 !) 
38 7 
800 <? 
322.5 
203 2 
256.0 
287.4 
143.7 
11.3 
<2 
9.5 
14.3 
9.5 
6.0 
4.0 
1.1 
<2 
16.0 
21.4 
18.0 
12.0 
7.1 
2.8 
<2 
40.7 
53.0 
64.0 
43.9 
18.2 
6.2 
<2 
50.8 
57.0 
57.0 
4.5.3 
20.2 
5.7 
<2 
3.0 
3.8 
2.5 
1 .6 
1.1 
1 .o 
<2 
5.0 
7.1 
4.8 
3.8 
2.4 
1 .o 
<2 
8.0 
12.4 
8.0 
5.8 
4.3 
1.2 
<2 
11.3 
14 3 
13.3 
8.0 
fl.4 
1.4 
< 2  
12.7 
19.0 
17.0 
8.0 
6.4 
1 .4 
1 2  
18.0 
24.0 
19.0 
14.3 
8.5 
3.7 
<2 
64.0 
87.7 
82.4 
56.4 
23.4 
97 
<z 
71.8 
90.5 
80.0 
64.0 
32.0 
8.0 
<2 
5.1 
6.34 
5.0 
3.6 
2.2 
1.4 
<2 
12.0 
12.7 
10.1 
8.0 
6.4 
3.2 
<2 
12 4 
13.2 
16.0 
0 7 
7.1 
3.7 
<2 
16.0 
20.2 
25 4 
16.0 
12 7 
4.C 
400-mg doses, and a titer of 1:8 was seen for 8 h 
following 800 mg. 
The urine data showed markedly higher titers than 
plasma. For Escherichia coli, Stuphylococcur saprophyticus, 
Proteus rnirabilis and Enrerococcur faecalis a mean titer of 
> 1 :8 was observed in the 18-24-h sample after 200 mg 
and in the 24-36 h sample after 400 mg. Pseudornonar 
aeruginosa, being less susceptible, demonstrated a titer of 
> 1:8 in the 18-24 h sample for the 600-mg dose. The 
results for this pathogen were somewhat less consistent 
than for the other pathogens. 
DISCUSSION 
The interpretation of serum bactericidal titer is subject 
to some controversy IS] .  Serial dilutions of a patient's 
serum obtained during therapy measure both the 
susceptibility of the pathogen and the combined effects 
of the inherent variations found in drug absorption, 
elimination, binding to serum proteins and the 
presence of antimicrobial metabolites. Hence the 
bactericidal titer measures the magnitude of the anti- 
microbial effect relative to the MBC. In this study, a 
titer of at least 1:8 was taken as significant, and this 
ensures that there is measurable bactericidal activity in 
a patient's serum for at  least a further three half-lives, 
which in the case of gatifloxacin is between 6 and 7 h 
161. In the clinically testing situation of streptococcal 
endocarditis, titers 5 1 :4 have been shown by Carrizosa 
and Kaye [7],  to be associated with therapeutic failures, 
although others suggest a peak bactericidal titer of 2 1:8 
to be associated with bacteriologic cure [81. Both 
these latter two studies were conducted in animals. In 
patients with osteomyelitis, a peak titer of ?1:16 and a 
trough titer of >1:4 were accurate predictors of cure 
191. In inimunoconipromised patients, serum and 
urine titers of 2 1 %  and 21:4, respectively, predicted 
successful outcomes [lo]. Others have found less 
association between titer and success rl11. Although it 
appears probable that the clinically relevant titer is 
dependent upon the disease and the particular 
pathogens concerned, a titer of 21:8, which we 
considered as potentially clinically significant, is a 
reasonable compromise. 
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Table 3 Urine bactericidal activity of gatifloxacin (as reciprocal of geometric mean titer) at differing collection intervals 
post-dose 
~ ~~ 
Time Dose Escherichia coli Staphylococcus saprophyticus Proteus mirabilis Pseudomonas aeruginosa Enterococcus faecalis 
(h) (mg) 
0 
&3 
3 4  
6-9 
9-12 
12-1 8 
18-24 
24-36 
0 
0-3 
3 4  
6-9 
9-12 
12-18 
18-24 
24-36 
0 
0-3 
3-6 
6-9 
9-1 2 
12-18 
18-24 
24-36 
0 
0-3 
3-6 
6-9 
9-1 2 
12-18 
18-24 
24-36 
200 <2 
228.1 
181.0 
95.9 
42.7 
67.8 
53.8 
6.7 
400 <2  
526.4 
1007.9 
966.5 
504.0 
599.3 
475.7 
110.4 
600 < 2  
847.6 
1097.5 
1260.7 
776.1 
1090.6 
961.5 
199.0 
800 <2  
3251.0 
1448.2 
1625.5 
812.8 
1448.2 
1290.2 
322.5 
<2  
215.3 
203.2 
101.6 
38.1 
60.4 
50.8 
7.6 
< 2  
140.8 
242.8 
149.3 
140.2 
89.4 
76.8 
24.9 
< 2  
225.7 
315.2 
362.0 
294.1 
309.3 
290.4 
56.4 
<2  
456.1 
322.5 
181.0 
228.1 
203.2 
64.0 
287.4 
< 2  
36.3 
16.0 
16.0 
6.7 
12.0 
8.5 
2.0 
<2 
222.9 
408.3 
317.9 
126.5 
204.2 
189.5 
18.3 
< 2  
28.2 
36.8 
68.6 
48.5 
36.3 
41.2 
9.1 
<2  
101.6 
32.0 
35.9 
28.5 
28.5 
45.3 
9.0 
<2 
7.1 
12.0 
5.7 
3.0 
2.5 
1.7 
1.1 
< 2  
15.0 
21.4 
18.2 
8.5 
11.3 
6.7 
1.7 
< 2  
13.2 
19.7 
18.4 
13.0 
12.4 
10.3 
2.9 
< 2  
22.6 
18.0 
18.0 
9.0 
11.3 
12.7 
4.0 
< 2  
107.6 
53.8 
50.8 
25.4 
35.9 
24.0 
3.4 
<2  
107.0 
139.1 
116.5 
59.0 
53.4 
33.1 
10.5 
< 2  
136.3 
207.9 
181.0 
147.0 
175.4 
136.3 
26.5 
<2 
256.0 
143.7 
181.0 
90.5 
128.0 
101.6 
32.0 
Applying this criterion to the results obtained in 
serum, it would appear that a dose of 400-600 mg of 
gatifloxacin once daily should be efficacious in the 
treatment of systemic infections caused by Staphylococcus 
auveus, the Enterobacteriaceae (other than those resistant 
to fluoroquinolones) and Acinetobactev baumanii. Strepto- 
coccus pneumoniae, being less susceptible than many of the 
above strains, may require a higher dose or an increased 
dosing frequency when infecting those sites where the 
agent is not concentrated. However, in the respiratory 
tract, it has been shown that fluoroquinolones are 
concentrated, the extent being dependent upon the 
anatomic site (sputum, bronchial mucosa, epithelial 
lining fluid or alveolar macrophage) [12]. 
As would be expected, a lower dose will probably 
be effective in the treatment of urinary tract infections, 
with the exception of Pseudomonas aeruginosa. A once- 
daily dose of 200 mg of gatifloxacin was bactericidal at 
a titer of >1:8 for 18-24 h, and a 400-mg dose gave 
24-36-h titers of >1:8, suggesting that a single dose 
might be effective. A 600-mg daily dose might be 
preferable to treat Pseudomonas aeruginosa urinary tract 
infections. This point should be addressed by detailed 
clinical trials. 
In conclusion, this study demonstrates that 
gatifloxacin should be efficacious in the treatment of a 
wide range of infections. 
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